Stem Cell Eye Therapy Shows Promise

Reporting inThe Lancet, researchers write that a
preliminary study shows embryonic stem cell therapy in two
patients with macular degeneration was safe. Results suggest
the patients' vision improved slightly. Dr. Robert Lanza, Chief
Scientific Officer of Advanced Cell Technology and co-author of
the study, discusses the trial.

See the original post:
Stem Cell Eye Therapy Shows Promise

Vet-Stem Announces Milestone of 8,000 Animals Treated With Vet-Stem Cell Therapy

POWAY, CA– – Vet-Stem, Inc. today announced that over 8,000 animals have now been treated with Vet-Stem cell therapy.Vet-Stem began providing stem cells to veterinarians in 2004 and has now provided stem …

Read more:
Vet-Stem Announces Milestone of 8,000 Animals Treated With Vet-Stem Cell Therapy

Genetic Mutation That Triggers Pancreatic Cancer Identified

Scientists at The University of Texas MD Anderson Cancer Center have identified a self-perpetuating “loop” of molecular activity that fuels pancreatic cancer by linking two signature characteristics of the disease – Kras, a gene that serves as a molecular on-off switch, but gets stuck on the “on” position when mutated, and NF-κB, a protein complex that controls activation of genes. In addition …

Read more:
Genetic Mutation That Triggers Pancreatic Cancer Identified

Genetic abnormalities may cause cerebral palsy, study suggests

For years it was thought that a difficult birth and other perinatal factors were the leading causes of cerebral palsy (CP), a group of disorders that can involve brain and nervous system functions such as movement, learning, hearing, seeing and thinking. Now, researchers suggest that the majority of cerebral palsy causes may in fact be caused by genetic abnormalities.

See the original post:
Genetic abnormalities may cause cerebral palsy, study suggests

Genetic variation that raises risk of serious complication linked to osteoporosis drugs identified

Researchers have identified a genetic variation that raises the risk of developing serious necrotic jaw bone lesions in patients who take bisphosphonates, a common class of osteoclastic inhibitors.

Visit link:
Genetic variation that raises risk of serious complication linked to osteoporosis drugs identified

Mom running Augusta Half Marathon for sick children

Stephanie Brantley decided her fourth time running in next month's Augusta Half Marathon was the right time to raise awareness and money for cystic fibrosis, an inherited disease that affects her three children.

See more here:
Mom running Augusta Half Marathon for sick children

Third Time's The Charm for Approval of Amylin Diabetes Drug

Updates with stock prices, company comment. SAN DIEGO (TheStreet) — Amylin Pharmaceuticals received U.S. approval Friday for its diabetes drug Bydureon, setting the stage for a commercial battle against an established rival drug from Novo Nordisk. Bydureon's U.S. approval comes on its third attempt. The U.S. Food and Drug Administration rejected the diabetes drug last in October 2010, asking …

More here:
Third Time's The Charm for Approval of Amylin Diabetes Drug

Amylin's long-delayed diabetes drug gets FDA nod

Amylin Pharmaceuticals won approval Friday for its long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections than the company's 7-year old diabetes medicine, Byetta.

Read this article:
Amylin's long-delayed diabetes drug gets FDA nod

US FDA approves Amylin's diabetes drug

WASHINGTON (Reuters) – Amylin Pharmaceuticals won U.S. approval
on Friday for its "lw_1327701069_6">Bydureon "lw_1327701069_4">diabetes drug, a long-awaited victory
for the company's most promising product.

After two delays, the "lw_1327701069_1">Food and Drug Administration approved
once-weekly injectable Bydureon for treating adults with
Type 2
diabetes
, the kind linked to poor diet and lack of
exercise. Bydureon is a longer-acting form of "yshortcuts" id="lw_1327701069_2">Amylin's older Byetta
treatment.

Shares of Amylin and partner "lw_1327701069_5">Alkermes, which provided some
technology for the medicine, were halted ahead of the
announcement of the FDA's decision.

More than 300 million people worldwide suffer from diabetes,
including nearly 26 million Americans. They run a high risk of
heart disease, stroke, kidney failure, blindness and limb loss.

Bydureon is seen as Amylin's most important new drug, and
critical to its future earnings growth, with analysts
estimating peak sales of close to $1 billion.

But after repeated delays in gaining approval in the United
States, the medicine faces a daunting competitive landscape.

Novo Nordisk's Victoza, another injectable "yshortcuts" id="lw_1327701069_3">diabetes medicine, has
had almost two extra years to gain traction with patients and
doctors. The delays have also given time for potential rivals
from GlaxoSmithKline Plc and Sanofi to catch up.

The FDA had rejected Bydureon twice before, most recently in
October 2010, asking for more data on potential side effects to
the heart. A trial of Bydureon in July found no link between
the drug and changes in heart rhythms, the company said.

However, as a condition of approval, the FDA on Friday said
Amylin must conduct another long-term clinical trial by 2018 to
study heart-related side effects from Bydureon.

WITHOUT LILLY

Taken once a week, Bydureon has been viewed as crucial to
sustaining the franchise started by the twice-daily Byetta.

Investors are closely watching whether Amylin will be able to
pull off a successful launch without the help of long-time
partner Eli Lilly & Co after the two companies broke off
their diabetes partnership in November. Alkermes would also get
royalties from the sales of Bydureon.

Amylin said Bydureon would be available in U.S. pharmacies
starting in February.

Victoza, which is injected daily, proved superior to Bydureon
in controlling blood sugar levels, trial results published last
March showed.

But Bydureon may get a boost because of its more convenient
dosing.

Analysts at Deutsche Bank said they expect peak Bydureon sales
of $1.5 billion, above market forecasts of $940 million by
2016, because of its convenience compared with Victoza.

Bydureon, Byetta and Victoza belong to the new GLP-1 class of
therapies that stimulate insulin production when blood sugar
levels become too high. They can also prompt weight loss, a
benefit because obesity is a leading cause of diabetes.

European regulators approved Bydureon as a treatment for Type 2
diabetes in April 2011.

(Reporting by Anna Yukhananov, additional reporting by Deena
Beasley in Los Angeles; Editing by Tim Dobbyn and Stever
Orlofsky)

See the original post:
US FDA approves Amylin's diabetes drug

Winter Symposium 2012 – Personalized Medicine Q


26-01-2012 02:43 Genome British Columbia Winter Symposium 2012 – Personalized Medicine Q

Continue reading here:
Winter Symposium 2012 – Personalized Medicine Q

Saladax Biomedical, Inc. Announces the Resignation of Edward L. Erickson as President and Chief Executive Officer

BETHLEHEM, Pa., Jan. 27, 2012 /PRNewswire/ – Saladax Biomedical, Inc., a privately-held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for …

See the original post here:
Saladax Biomedical, Inc. Announces the Resignation of Edward L. Erickson as President and Chief Executive Officer

Cell Watchers

The Broad Institute has received a $32.5 million grant from the Klarman Family Foundation to open the Klarman Cell Observatory , a project focused on “deciphering how human cells are wired,” an institute press release says.

Read the rest here:
Cell Watchers

New discovery paves way for genetic screening test

Researchers at the Columbia University College of Dental Medicine have identified a genetic variation that raises the risk of developing serious necrotic jaw bone lesions in patients who take bisphosphonates, a common class of osteoclastic inhibitors.

Continue reading here:
New discovery paves way for genetic screening test

Diabetes leg, foot amputations see dramatic drop

New report finds huge decline in lower extremity amputations in past decade

Originally posted here:
Diabetes leg, foot amputations see dramatic drop

Study pinpoints genetic variation that raises a risk linked to bisphosphonates

( Columbia University Medical Center ) Researchers at the Columbia University College of Dental Medicine have identified a genetic variation that raises the risk of developing serious necrotic jaw bone lesions in patients who take bisphosphonates, a common class of osteoclastic inhibitors. The discovery paves the way for a genetic screening test to determine who can safely take these drugs.

Link:
Study pinpoints genetic variation that raises a risk linked to bisphosphonates

UC Davis researcher develops model to foster new drug development to treat pain and epilepsy – Video


12-12-2011 16:11 Drawing on X-ray crystallography and experimental data, as well as a software suite for predicting and designing protein structures, a UC Davis School of Medicine researcher has developed an algorithm that predicts what has been impossible to generate in the laboratory: the conformational changes in voltage-gated sodium channels when they are at rest or actively transmitting a signal in muscle and nerve cells. See press release at: www.ucdmc.ucdavis.edu

View original post here:
UC Davis researcher develops model to foster new drug development to treat pain and epilepsy – Video

IIB Medical Center Patient Coordinator Video Blog #1 – Video


27-12-2011 15:47 IIB was born as a response to the great need for successful new technologies and alternative immunotherapies. The innovation of existing therapies for the benefit of many types of patients. Through the use of modern and smart medicine obtaining a better quality of life and prolong survival in patients suffering from cancer, viral infections, degenerative and autoimmune diseases is now reality.

Read more:
IIB Medical Center Patient Coordinator Video Blog #1 – Video

Craig Venter: Understanding Our Genes – A Step to Personalized Medicine | CIRM Spotlight on Genomics – Video


24-01-2012 10:25 On January 17th, 2012, the CIRM Governing Board heard from scientists and a patient about the essential role of genomics in the development of stem cell based therapies.

Originally posted here:
Craig Venter: Understanding Our Genes – A Step to Personalized Medicine | CIRM Spotlight on Genomics – Video

#NDPLDR Debate Question 2: Drug Law Reform – Video


24-01-2012 17:08 My Previous Question to the Leadership Candidates: youtu.be Canadian Court Decisions Regarding Cannabis: www.ontariocourts.on.ca www.ontariocourts.on.ca Portugal Decriminalizes Drugs, Crime Lowers: www.cato.org www.cato.org www.time.com www.cato.org Cannabis Research Suppressed By US Government: In 1944 the mayor of New York City commissioned a report on cannabis use, the report found that cannabis use should have no criminal penalty. www.druglibrary.org This is the report that was commissioned by President Nixon in the 1970′s, President Nixon ignored the findings of this report and declared a war on drugs despite evidence that this would cause more harm than good. www.druglibrary.org In the thirties Cannabis was criminalized, what is often lost to history is that the medical community was mostly opposed to this prohibition, cannabis was used in many medical preparations and was a valued part of medicine until it was outlawed

Read more:
#NDPLDR Debate Question 2: Drug Law Reform – Video

Medical Tyranny: Infowars Nightly News – Video


18-01-2012 03:45 Tonight on the Tuesday, January 17, 2012 edition of the Infowars Nightly News: • Alex interviews Infowars contributing writer and vaccine researcher Curt Linderman Sr. about the medical tyranny hoax that ceaseless continues in trying to trick the public into complying with “mandatory” vaccinations. In the latest episode, a Pennsylvanian doctor reported her patient to a state trooper, as well as Children and Youth Services Department, after the mother, Rachel Garmon, refused dangerous inoculations for her son.

More:
Medical Tyranny: Infowars Nightly News – Video

Integrative Medicine Conference January 2011, Aging Medicine, Adrenaline Fatigue Treatment – Video


11-12-2010 05:12 www.theifim.com The IFIM Orlando Conference Friday, January 28, 2011 8 AM – Sunday, January 30, 2011 12:00 PM (Eastern Time) Are you trying to break in to the new health care system of integrative medicine and don’t know who to turn to? Are you looking for a source that can guide you, with experience, to develop the integrative medicine practice of your dreams? Are you on Google looking for: Aging medicine Conference, Orlando anti aging Expo 2011, treatment for adrenal exhaustion, Integrative Medicine conference,, adrenaline fatigue treatment or adrenals fatigue Florida, then you need theIFIM.com

Visit link:
Integrative Medicine Conference January 2011, Aging Medicine, Adrenaline Fatigue Treatment – Video

Paula Deen: Diabetes backlash – Video


20-01-2012 18:22 Celebrity chef Paula Deen is under fire since her disclosure that she is a paid spokesperson for a diabetes drug. CBS News correspondent Whit Johnson reports. Then, chef Jose Andres weighs in on the controversy.

See the original post here:
Paula Deen: Diabetes backlash – Video

Mom running Augusta half marathon for ill children

Stephanie Brantley, a mother of three children with the life-threatening illness cystic fibrosis, will run the Augusta half marathon to raise money for disease research.

The rest is here:
Mom running Augusta half marathon for ill children

Study Pinpoints Genetic Variation that Raises Risk of Serious Complication Linked to Osteoporosis Drugs

Researchers at the Columbia University College of Dental Medicine have identified a genetic variation that raises the risk of developing serious necrotic jaw bone lesions in patients who take bisphosphonates, a common class of osteoclastic inhibitors.

Read more from the original source:
Study Pinpoints Genetic Variation that Raises Risk of Serious Complication Linked to Osteoporosis Drugs

Smartphone Technology Meets Personalized Medicine in Everist Genomics' CardioDefender Diagnostic System

ANN ARBOR, Mich., Jan. 27, 2012 /PRNewswire/ – Everist Genomics announced today that Executive Vice Chairman Alex Charlton will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference , January 30, 2012, in Munich

See more here:
Smartphone Technology Meets Personalized Medicine in Everist Genomics' CardioDefender Diagnostic System